IL155919A0 - Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia - Google Patents

Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia

Info

Publication number
IL155919A0
IL155919A0 IL15591901A IL15591901A IL155919A0 IL 155919 A0 IL155919 A0 IL 155919A0 IL 15591901 A IL15591901 A IL 15591901A IL 15591901 A IL15591901 A IL 15591901A IL 155919 A0 IL155919 A0 IL 155919A0
Authority
IL
Israel
Prior art keywords
rosuvastatin
treatment
familial hypercholesterolemia
heterozygous familial
heterozygous
Prior art date
Application number
IL15591901A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9903629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL155919(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL155919A0 publication Critical patent/IL155919A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL15591901A 2000-11-22 2001-11-16 Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia IL155919A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0028429.9A GB0028429D0 (en) 2000-11-22 2000-11-22 Therapy
PCT/GB2001/005041 WO2002041895A1 (en) 2000-11-22 2001-11-16 Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia

Publications (1)

Publication Number Publication Date
IL155919A0 true IL155919A0 (en) 2003-12-23

Family

ID=9903629

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15591901A IL155919A0 (en) 2000-11-22 2001-11-16 Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia
IL155919A IL155919A (en) 2000-11-22 2003-05-14 (e) - 7 - [4 - (4 - fluorophenyl) - 6 - isopropyl - 2 - [methyl ( methylsulfonyl) amino] pyrimidin - 5 - yl] (3r, 5s) - dihydroxyhept - 6 - enoic acid, or a pharmaceutically acceptable salt thereof, for use as a medicament for the treatment of heterozygous familial hypercholesterolemia

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL155919A IL155919A (en) 2000-11-22 2003-05-14 (e) - 7 - [4 - (4 - fluorophenyl) - 6 - isopropyl - 2 - [methyl ( methylsulfonyl) amino] pyrimidin - 5 - yl] (3r, 5s) - dihydroxyhept - 6 - enoic acid, or a pharmaceutically acceptable salt thereof, for use as a medicament for the treatment of heterozygous familial hypercholesterolemia

Country Status (34)

Country Link
US (1) US6858618B2 (enExample)
EP (1) EP1339409B1 (enExample)
JP (2) JP5062940B2 (enExample)
KR (1) KR100815042B1 (enExample)
CN (1) CN1268339C (enExample)
AR (1) AR031766A1 (enExample)
AT (1) ATE394103T1 (enExample)
AU (2) AU1416502A (enExample)
BG (1) BG66009B1 (enExample)
BR (1) BR0115511A (enExample)
CA (1) CA2429263C (enExample)
CY (1) CY1110428T1 (enExample)
CZ (1) CZ301583B6 (enExample)
DE (1) DE60133921D1 (enExample)
DK (1) DK1339409T3 (enExample)
EE (1) EE05507B1 (enExample)
ES (1) ES2305118T3 (enExample)
GB (1) GB0028429D0 (enExample)
HU (1) HUP0301380A3 (enExample)
IL (2) IL155919A0 (enExample)
IS (1) IS6819A (enExample)
MX (1) MXPA03004336A (enExample)
MY (1) MY134902A (enExample)
NO (1) NO326245B1 (enExample)
NZ (1) NZ525754A (enExample)
PL (1) PL365386A1 (enExample)
PT (1) PT1339409E (enExample)
RU (1) RU2294744C2 (enExample)
SI (1) SI1339409T1 (enExample)
SK (1) SK6212003A3 (enExample)
TW (1) TWI238720B (enExample)
UA (1) UA75614C2 (enExample)
WO (1) WO2002041895A1 (enExample)
ZA (1) ZA200303636B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
JP2006524710A (ja) * 2003-04-25 2006-11-02 ギリアード サイエンシーズ， インコーポレイテッド キナーゼインヒビターホスホネート抱合体
PT1628685E (pt) 2003-04-25 2011-03-16 Gilead Sciences Inc Análogos de fosfonatos antivirais
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
EP1562912A2 (en) * 2003-08-28 2005-08-17 Teva Pharmaceutical Industries Limited Process for preparation of rosuvastatin calcium
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US7432273B2 (en) * 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
CA2546701C (en) 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
DE602004032465D1 (de) * 2003-12-02 2011-06-09 Teva Pharma Referenzstandard zur charakterisierung von rosuvastatin
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
ZA200610167B (en) * 2004-05-26 2008-07-30 Kgksynergize Inc Functional foods comprising flavonoids and tocotrienols and methods thereof
CA2573857A1 (en) * 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
BRPI0512690A (pt) 2004-07-27 2007-11-27 Gilead Sciences Inc análogos de fosfonato de compostos inibidores de hiv
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
PL1851206T3 (pl) * 2005-02-22 2013-01-31 Teva Pharma Rozuwastatyna i jej wolne od alkilenowych eterów sole oraz sposób ich wytwarzania
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
US7868169B2 (en) * 2005-08-16 2011-01-11 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin intermediate
US9427437B2 (en) 2008-01-31 2016-08-30 The Trustees Of The University Of Pennsylvania Hypercholesterolemia and tendinous injuries
US8383614B2 (en) * 2008-01-31 2013-02-26 The Trustees Of The University Of Pennsylvania Hypercholestrolemia and tendinous injuries
EP2298745B1 (en) 2008-05-27 2014-09-03 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
PT2307435E (pt) * 2008-07-08 2012-09-19 Gilead Sciences Inc Sais de compostos inibidores de vih
CA2884481C (en) 2012-09-17 2021-04-27 Madrigal Pharmaceuticals, Inc. Method of synthesizing thyroid hormone analogs and polymorphs thereof
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
PT3661937T (pt) 2017-08-01 2021-09-24 Gilead Sciences Inc Formas cristalinas de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofurano-2-il)oxi)metil)(fenoxi)fosforil)-l-alaninato de etil (gs-9131) para tratamento de infeções virais
PH12021552979A1 (en) 2019-05-27 2023-10-09 Immatics Us Inc Viral vectors and their use in adoptive cellular therapy
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
WO2022165227A1 (en) * 2021-02-01 2022-08-04 Madrigal Pharmaceuticals, Inc. Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disorders
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2051907C1 (ru) * 1989-05-22 1996-01-10 Сандос АГ Способ получения 7-замещенной гептен-6-овой кислоты
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
TWI293877B (en) * 2000-09-20 2008-03-01 Rtp Pharma Inc Spray drying process and compositions of fenofibrate

Also Published As

Publication number Publication date
HUP0301380A3 (en) 2007-03-28
ZA200303636B (en) 2004-08-12
HUP0301380A2 (hu) 2003-10-28
AU2002214165B9 (en) 2013-07-04
MXPA03004336A (es) 2003-08-19
SK6212003A3 (en) 2003-11-04
ATE394103T1 (de) 2008-05-15
EE200300239A (et) 2003-08-15
TWI238720B (en) 2005-09-01
AU2002214165B2 (en) 2006-12-14
PT1339409E (pt) 2008-07-07
NO20032292L (no) 2003-07-17
US20040072852A1 (en) 2004-04-15
CA2429263A1 (en) 2002-05-30
CA2429263C (en) 2009-03-17
AU1416502A (en) 2002-06-03
WO2002041895A1 (en) 2002-05-30
JP2010031047A (ja) 2010-02-12
AR031766A1 (es) 2003-10-01
EE05507B1 (et) 2012-02-15
GB0028429D0 (en) 2001-01-10
JP2004522714A (ja) 2004-07-29
IS6819A (is) 2003-05-19
CZ20031406A3 (cs) 2003-09-17
US6858618B2 (en) 2005-02-22
CZ301583B6 (cs) 2010-04-21
DK1339409T3 (da) 2008-09-08
IL155919A (en) 2009-09-01
HK1056691A1 (en) 2004-02-27
ES2305118T3 (es) 2008-11-01
CN1630520A (zh) 2005-06-22
NO20032292D0 (no) 2003-05-21
PL365386A1 (en) 2005-01-10
NO326245B1 (no) 2008-10-27
BG107811A (bg) 2004-03-31
DE60133921D1 (de) 2008-06-19
CN1268339C (zh) 2006-08-09
JP5062940B2 (ja) 2012-10-31
BG66009B1 (bg) 2010-10-29
UA75614C2 (uk) 2006-05-15
EP1339409B1 (en) 2008-05-07
BR0115511A (pt) 2003-12-30
MY134902A (en) 2007-12-31
KR20030048479A (ko) 2003-06-19
NZ525754A (en) 2004-10-29
CY1110428T1 (el) 2015-04-29
KR100815042B1 (ko) 2008-03-18
RU2294744C2 (ru) 2007-03-10
EP1339409A1 (en) 2003-09-03
SI1339409T1 (sl) 2008-08-31

Similar Documents

Publication Publication Date Title
AU1416502A (en) Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia
GB0109414D0 (en) Well treatment fluids and methods for the use thereof
GB0109537D0 (en) Well treatment fluids and methods for the use thereof
PT1757606E (pt) Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
AU2002352389A1 (en) Piperazine compounds and their phamaceutical use
GB9912411D0 (en) Compounds useful in therapy
GB9912413D0 (en) Compounds useful in therapy
IL139899A (en) Uracil compounds and use thereof
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
GB0105613D0 (en) Pharmaceutically effective compounds and their use
GB9912410D0 (en) Compounds useful in therapy
HUP0401913A3 (en) Medicine for preventing and treating bromhidrosis
GB0119025D0 (en) Compounds and their therapeutic use
GB9912416D0 (en) Compounds useful in therapy
GB9912415D0 (en) Compounds useful in therapy
GB2376943B (en) Compounds and their therapeutic use
GB0112237D0 (en) Compounds and their therapeutic use
AU2002364385A8 (en) Implantable device and the use thereof
CA86254S (en) Disposable diaper or the like
HK1063015A (en) Carbamate compounds for use in the treatment of pain
AU2002357468A1 (en) Use of 2-acylindoles in the treatment of tumors
GB9909843D0 (en) Compounds and their use
GB0018885D0 (en) Compounds and their therapeutic use
GB0018886D0 (en) Compounds and their therapeutic use
GB0018888D0 (en) Compounds and their therapeutic use